These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 20007676)
41. [Management of phosphate in chronic kidney disease--Phosphorus control by hemodialysis with long treatment time]. Tanaka M Clin Calcium; 2009 Feb; 19(2):194-7. PubMed ID: 19182358 [TBL] [Abstract][Full Text] [Related]
42. Current world literature. Mineral metabolism. Renal pathophysiology. Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):488-501. PubMed ID: 23736844 [No Abstract] [Full Text] [Related]
43. Why are some dialysis patients chronically hypotensive in the absence of heart disease and volume depletion? Palmer BF Semin Dial; 2011; 24(4):404-5. PubMed ID: 21851401 [No Abstract] [Full Text] [Related]
44. FGF-23 in dialysis patients: ready for prime time? Zoccali C Nephrol Dial Transplant; 2009 Apr; 24(4):1078-81. PubMed ID: 19147667 [No Abstract] [Full Text] [Related]
45. New insights to fibroblast growth factor 23 in kidney transplant. Ix JH J Am Soc Nephrol; 2011 May; 22(5):799-801. PubMed ID: 21474565 [No Abstract] [Full Text] [Related]
46. Diagnosis and management of insomnia in dialysis patients. Novak M; Shapiro CM; Mendelssohn D; Mucsi I Semin Dial; 2006; 19(1):25-31. PubMed ID: 16423179 [TBL] [Abstract][Full Text] [Related]
47. [Principles in the care of chronic kidney diseases from early diagnosis to treatment with the mechanical kidney]. Orv Hetil; 1975 Apr; 116(14):803-6. PubMed ID: 1118151 [No Abstract] [Full Text] [Related]
49. Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us? Krane V; Wanner C Am J Kidney Dis; 2005 Mar; 45(3):607-9. PubMed ID: 15754285 [No Abstract] [Full Text] [Related]
50. Mineral metabolism and mortality in patients with chronic kidney disease. Young EW Adv Chronic Kidney Dis; 2007 Jan; 14(1):13-21. PubMed ID: 17200039 [TBL] [Abstract][Full Text] [Related]
51. Historical perspective of pregnancy in chronic kidney disease. Hou S Adv Chronic Kidney Dis; 2007 Apr; 14(2):116-8. PubMed ID: 17395113 [TBL] [Abstract][Full Text] [Related]
52. Target hemoglobin level for EPO therapy in CKD. Parfrey PS Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399 [No Abstract] [Full Text] [Related]
53. [Cardiovascular, renal and other chronic diseases. Early intervention is necessary in chronic kidney disease]. Martín de Francisco AL; Aguilera L; Fuster V Nefrologia; 2009; 29(1):6-9. PubMed ID: 19240765 [No Abstract] [Full Text] [Related]
54. Mineral metabolism: confusion to clarity. Bushinsky DA; Wolf MS Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):353-4. PubMed ID: 22622652 [No Abstract] [Full Text] [Related]
55. Second chances. Dart A Nat Rev Cancer; 2018 Sep; 18(9):531. PubMed ID: 30022145 [No Abstract] [Full Text] [Related]
56. Second chances. Xu Y Science; 2022 May; 376(6594):770. PubMed ID: 35549432 [No Abstract] [Full Text] [Related]
58. Second chances in mineral metabolism. Wolf M Clin J Am Soc Nephrol; 2010 Jan; 5(1):1-3. PubMed ID: 20007676 [No Abstract] [Full Text] [Related]
59. FGF23: a key player in mineral and bone disorder in CKD. Komaba H; Fukagawa M Nefrologia; 2009; 29(5):392-6. PubMed ID: 19820750 [TBL] [Abstract][Full Text] [Related]
60. Mineral and bone metabolism in dialysis: towards unified patient care? Pelletier S; Fouque D Nephrol Dial Transplant; 2011 Jan; 26(1):7-9. PubMed ID: 21106773 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]